To the best of our knowledge, this is the first report demonstrating the potential of JNJ-64619178, PRMT5 inhibitor as a radiosensitizer, and FIR-induced NED inhibitor for prostate cancer treatment. Here, PRMT5 is linked to prostate cancer.